FDA Postdoctoral Fellowship in Cardiovascular Devices
*Applications will be reviewed on a rolling-basis.
SUBMIT APPLICATION THROUGH EXTERNAL LINK. SUBMIT RESUME WITH APPLICATION.
A research opportunity is currently available with the Office of the Commissioner (OC) Office of Women's Health (OWH), U.S. Food and Drug Administration (FDA). The project will be located at the Center for Devices and Radiological Health (CDRH) located in Silver Spring, Maryland.
The selected participant will be part of a collaborative team striving to conduct exploratory research to investigate sex-based differences in the performance of paclitaxel containing cardiovascular devices. This project is multi-faceted with focus areas involved in [1] developing a computational model to estimate distribution of paclitaxel within atherosclerotic plaque, [2] setting up in vitro and ex vivo tissue/cell culture models to investigate microvascular response to paclitaxel, and [3] conducting statistical data analysis of available post-market data.
Anticipated Appointment Start Date: August 3, 2020
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
Qualifications
The qualified candidate should have received a doctoral degree in one of the relevant fields, or be currently pursuing the degree and will reach completion by the start date of the appointment. Degree must have been received within five years of the appointment start date.
If you have questions, send an email to ORISE.FDA.OC.other@orau.org. Please include the reference code for this opportunity (FDA-OWH-2020-0006) in your email.